← Leaderboards
Alberto Moreno
Emory University
$7,414,543
Attributed
$9,068,465
Total exposure
15
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $852K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,068,465 · 15
By mechanism
R01$5,956,966 · 3
R21$1,941,598 · 4
R56$843,761 · 1
P51$326,140 · 7
Top collaborators
- Ravi S Kane3 shared
- Gabriele Neumann3 shared
Most similar at Emory University
Same institution · by research overlap
- Mary R Galinski$18,988,233
- Tracey Jane Lamb$8,710,457
Others in their field
Top investigators on “Malaria”
- Lawrence Corey · Fred Hutchinson Cancer Center$227,738,417
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$227,738,417
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$82,291,297
- Stephen Lev Hoffman · Sanaria, Inc.$79,440,588
- Constance Ann Benson · University Of California, San Diego$65,790,143
- David Heimbrook · Leidos Biomedical Research, Inc.$61,561,099
Research focus
MalariaVaccinesProteinsDesignImmune ResponseAntigensParasitesPlasmodiumVaccine DevelopmentInfectionImmunogenicityAntibodiesBaseLife Cycle StagesProphylacticImmunityMalaria VaccinesStagingRecombinant ProteinsErythrocytesAreaCd4 Positive T LymphocytesGeneticChimeric Proteins
Grant awards (30)
Engineering Protein Antigens and their Presentation from Multivalent Scaffolds$812,281
R01 · FY2025 · AI
Engineering Protein Antigens and their Presentation from Multivalent Scaffolds$816,638
R01 · FY2024 · AI
Engineering Protein Antigens and their Presentation from Multivalent Scaffolds$851,964
R01 · FY2023 · AI
Development of simianized mice to study the biology of relapsing malaria parasites$218,384
R21 · FY2019 · AI · contact PI
Development of simianized mice to study the biology of relapsing malaria parasites$263,440
R21 · FY2018 · AI · contact PI
Novel DC targeted adenovirus vector for malaria vaccine development$214,025
R21 · FY2017 · AI · contact PI
Novel DC targeted adenovirus vector for malaria vaccine development$271,775
R21 · FY2016 · AI · contact PI
Optimization of chimeric multi-stage immunogens for malaria vaccine development$843,761
R56 · FY2014 · AI · contact PI
Chimeric hybrid transmission blocking vaccine for malaria$220,000
R21 · FY2013 · AI · contact PI
Coadministration of capsid modified adenovirus for malaria vaccine development$211,737
R21 · FY2013 · AI · contact PI
Coadministration of capsid modified adenovirus for malaria vaccine development$278,237
R21 · FY2012 · AI · contact PI
Chimeric hybrid transmission blocking vaccine for malaria$264,000
R21 · FY2012 · AI · contact PI
MODULAR CHIMERIC VACCINES TAILORED FOR MALARIA PARASITES$41,159
P51 · FY2011 · RR · contact PI
Modular Chimeric Vaccines tailored for malaria parasites$398,429
R01 · FY2010 · AI · contact PI
MODULAR CHIMERIC VACCINES TAILORED FOR MALARIA PARASITES$54,827
P51 · FY2010 · RR · contact PI
Modular Chimeric Vaccines tailored for malaria parasites$402,453
R01 · FY2009 · AI · contact PI
MODULAR CHIMERIC VACCINES TAILORED FOR MALARIA PARASITES$54,800
P51 · FY2009 · RR · contact PI
Modular Chimeric Vaccines tailored for malaria parasites$402,453
R01 · FY2008 · AI · contact PI
MODULAR CHIMERIC VACCINES TAILORED FOR MALARIA PARASITES$35,600
P51 · FY2008 · RR · contact PI
Modular Chimeric Vaccines tailored for malaria parasites$410,248
R01 · FY2007 · AI · contact PI
NOVEL LINEAR PEPTIDE UNIVERSAL MALARIA VACCINES$31,598
P51 · FY2007 · RR · contact PI
Modular Chimeric Vaccines tailored for malaria parasites$422,500
R01 · FY2006 · AI · contact PI
NOVEL LINEAR PEPTIDE UNIVERSALL MALARIA VACCINES$32,056
P51 · FY2006 · RR · contact PI
Novel Linear Peptide Universal Malaria Vaccines$400,000
R01 · FY2005 · AI
NOVEL LINEAR PEPTIDE UNIVERSALE MALARIA VACCINES$24,598
P51 · FY2005 · RR
Novel Linear Peptide Universal Malaria Vaccines$400,000
R01 · FY2004 · AI
NOVEL LINEAR PEPTIDE UNIVERSAL MALARIA VACCINES$27,505
P51 · FY2004 · RR
Novel Linear Peptide Universal Malaria Vaccines$400,000
R01 · FY2003 · AI
NOVEL LINEAR PEPTIDE UNIVERSALE MALARIA VACCINES$23,997
P51 · FY2003 · RR
Novel Linear Peptide Universal Malaria Vaccines$240,000
R01 · FY2002 · AI